Developer of revolutionizing medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments Subscription takes place from the 25th of March through the 12th of April, 2021 before listing on the Spotlight Stock Market with preliminary first trading day on the 5th of May, 2021.
The World Health Organization has identified infertility as a global health issue, affecting approximately 15 percent of the global population in the fertile age group. This is equal to around 60 million couples, being impacted by infertility. In half of the cases, the cause of infertility is the male factor. Spermosens is developing a revolutionizing technology for male fertility diagnostics and fertility treatment.
With Spermosens first product, JUNO- Checked, it will – for the first time – be possible to determine a sperms ability to fertilize the egg cell. This in turn enables the IVF clinic to choose the appropriate fertilization treatment. Today, around 85 percent of IVF treatments fail. Being able to determine the sperm’s ability to fertilize the egg cell is expected to cause to a reduction in the number of IVF-treatments. This leads to:
Reduced waiting period for childless couples
Less negative phycological effects
Reduced cost for the couples in treatment
Reduced need for hormonal treatments of the female
Increased capacity of each IVF clinic
Improved financial outlook for IVF clinics
”We estimate the global sales potential to be around five billion SEK per year, assuming that all of the 3,600 clinics, which we have identified as potential clients, make use of JUNO-Checked for all of their IVF treatments. We won’t be able to reach the entirety of the global market at once, but with our unique product offering and competitive edge, I predict that we will be able to capture a very high market share”.
Spermosens AB (publ) is listed on Spotlight Stockmarket. The share is traded under the ticker SPERM and ISIN-code SE0015346424.
Spotlight is an alternative market and does not have the same legal status as regulated market. Companies at Spotlight Stockmarket are subject to the rules of Spotlight and not the legal requirements for admission to trading on a regulated market. An investment in a company that is traded on Spotlight Stockmarket is riskier than an investment in a company that is traded on a regulated market.
Första handelsdag för Spermosens AB
SPERMOSENS AB meddelar att handel i bolagets aktier (kortnamn SPERM) och teckningsoptioner serie TO1 (SPERM TO1) inleds idag på Spotlight Stock Market i Stockholm.
Spermosens erhåller preliminärt patentgodkännande från Europapatentverket
Spermosens AB (’Spermosens’) meddelar idag att bolaget har erhållit en så kallad ”Intention to Grant” från Europapatentverket (EPO) avseende patentansökan som skyddar bolagets biosensor avsedd för användning inom In Vitro Fertilisering (IVF). Nästa steg i processen är ett formellt godkännande varefter patentet blir giltigt t o m 2039.
Board member since: 2020
Main occupation: Board professional
Shares: 30 000 direct
Options: 81 000 direct
Eva Nilsagård is currently the founder and CEO of Nilsagård Consulting AB. Eva holds an executive MBA in business management and organization as well as a master’s degree in accounting and finance from the Gothenburg School of Economics. Eva has been CFO at OptiGroup, Vitrolife and Plastal, SVP Strategy & Business development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva has a long experience of listed companies and over 10 years of experience as a mentor for young female managers.
Other current assignments: Nimbus Group AB, board member. Hansa Biopharma AB (publ), board member. Xbrane Biopharma AB, board member. Aktiebolaget Svensk Exportkredit, board member. IRRAS AB, board member. Addlife AB, board member. Bufab AB (publ), board member. Nilsagård Consulting AB, board member and CEO.
Board member since: 2019
Main occupation: Embryologist and Unit Manager, Laboratory, Reproductive Medicine Centre, Skåne University Hospital
Dr. Ingela Liljeqvist Soltic currently works as an embryologist and unit manager for laboratory and tissue establishment at the Center for Reproductive Medicine (RMC) at Skåne University Hospital. Ingela has a BSc in Biomedical Laboratory Technology from Lund University and a PhD in Biomedical Science.Ingela has previously worked as an embryologist at IVF Clinic Cura Öresund and at the pharmaceutical company Merck. Ingela has extensive experience from IVF and fertility issues.
Board member since: 2020
Main occupation: Investor and entrepreneur
Shares: 231 066 direct and via company
TO1: 75 066 direct and via company
John Moll is the founder of Torna Kapital AB, through which he invests in development companies. John has conducted studies in finance at Lund University and master´s studies in biotechnology at Lund University. John has a long experience as an entrepreneur and has founded and sold two companies, including in the health and pharmaceutical sector. As an experienced Lund-based investor, John has a wide network of contacts in the Öresund region.
Other current assignments: Aktiebolaget Lundgren, Nilsson & Moll, board member. Carbiotix AB (publ), board member. Qlife Holding AB (publ), board member. Qlife Aps, board member. Huskvarna Stadshotell AB, board member. Town&Country Resorts AB, board member. Acantor Holding AB, board member. Torna Kapital AB, board member.
Board member since: 2020
Main occupation: VP Sales & Marketing Galenica AB
Shares: 220 132 via company
TO1: 169 132 via company
Options: 27 000 direct
Sören Melsing Frederiksen currently holds the position of Vice President, Generics and Commercial Rx, ORIFARM GROUP A/S. Søren holds a B.A.Sc in Applied Science and a master´s degree in drug development. Søren has held several positions within LEO Pharma and as commercial manager for the Nordic region at Aspen Pharma. Søren has extensive experience in marketing and sales as well as the entire value chain in the pharmaceutical industry.
Other current assignments: VBM Ejendomsselkabet af 2007 Aps, board member. BotSupply ApS, board member. StenoCare A/S, board member. SML Holding ApS, board member and CEO. VBM LaboratorietA/S, board member.
Board member since: 2018
Main occupation: CSO Spermosens AB
Shares: 1 578 240 direct
Kushagr Punyani is founder and CSO for Spermosens AB. Kushagr holds a licentiate degree in engineering, microfluidic technology, from Lund University. From his studies in India together with Professor Sudha Srivastava, Punyani laid the foundation for Spermosens’ technology. Kushagr has also been involved in founding a number of companies that develop new technologies in medtech / pharmaceuticals.
Other current assignments: Diagonal Pharma AB, board member. Punyani Labs AB, board member.
Shares: 140 284 direct
TO1: 35 524 direct
Options: 162 000 direct
John Lempert studied law at Lund University and is by the National Board of Health and Welfare a certified dental technician. John has among other worked for Johnson & Johnson in international positions and in smaller entrepreneurial companies being responsible for developing new patented dental materials from development, through regulatory affairs and manufacturing to completed market entry and build-up.
John has also had assignments for the World Band and has more than 35 years of experience from business development in the medtech industry.
Shares: 12 876 direct
TO1: 12 876 direct
Cajsa Wramdemark, owner and founder of More than Finance AB, holds a Master of Science in International Business Administration and Economics from the School of Economics and Management, Lund University.
Cajsa has more than 20 years of experience within finance in both multi-national as well as SME companies within Life Science as well as other areas. She has had roles as CFO and Chief Accounting Manager. In addition to finance, Cajsa has been responsible for HR and Purchasing in previous roles.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: